The frst results of combined treatment of central serous chorioretinopathy using subthreshold micropulse laser exposure with 577 nm wavelength and injections of platelet autoplasma

Bibliography:
1 Chen G, Tzekov R, Li W, et al. Subfoveal choroidal thickness in central serous chorioretinopathy: A meta-analysis. PLoS ONE 2017 DOI: 10.1371 / journal. pone. 169152
2 Daruich A, Matet A, Diran A, et al. Central serous chorioretinopathy: Recent fndings and new physiopathology hypothesis. Prog Retin Eye Res 2015; (48): 82–118
3 Lai WY, Tseng CL, Wu TT, et al. Correlation between baseline retinal microstructures in spectral-domain optic coherence tomography and need for early intervention in central serous chorioretinopathy. BMJ Open Ophth 2017 DOI: 10.1136 / bmjophth-2016–0000548 4 Liew G, Quin G, Gillies M, et al. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 2013; (41): 201–14. 5 Moschos M, Brouzas D, Koutsandrea C, et al. Assessment of central serous chorioretinopathy by optical coherence tomography and multifocal electroretinography. Ophthalmologica 2007; (221): 292–8. 6 Nicholson B, Noble J, Forooghian F, et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58 (2): 103–26. 7 Sugiura A, Fujino R, Takemiya N, et al. The association between visual function and retinal structure in chronic central serous chorioretinopathy. Scientifc Reports 2017 DOI: 10.1038 / s41598-017-16339-9. 8 Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010; (149): 361–3. 9 Yu L, Shao Y, Chai Y, et al. Retinal microvasculature alteration in central serous chorioretinopathy. Molecular Medicine Reports 2018; (17): 2335–40. 10 Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 2008; (115): 169–73. 11 Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmologica 2008; (86): 126– 45 12 Dolar-Szczasny J, Swięch-Zubilewicz A, Mackiewicz J. Macular integrity assessment and fxation analysis in chronic centrals chorioretinopathy. J Ophthalmol 2018 DOI: 10.1155 / 2018 / 9479848 13 Imamura Y, Fujiwara T, Margolis R, et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; (29): 1469–73. 14 Kim YJ, Lee YG, Lee DW, et al. Selective retina Therapy with real-time feedback-controlled fosimetry for freating acute idiopathic central serous chorioretinopathy in Korean patients. J Ophthalmol 2018 DOI: 10.1155 / 2018 / 6027871 15 Nikkhah H, Karimi S, Ahmadieh H, et al. Intravitreal injection of antivascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline. J Ophthalmic Vis Res 2018; (13): 158–69. 16 Semeraro F, Russo A, Delcassi L, et al. Recurrent central serous chorioretinopathy after peripheral retinal laser photocoagulation: a case report. Eur J Ophthalmol 2013; 23 (2): 258–61. 17 Kang S, Park YG, Kim JR, et al. Selective retina therapy in patients with chronic central serous chorioretinopathy: a pilot study. Medicine 2016 DOI: 10.1097 / MD. 2524 18 Mehta PH, Meyerle C, Sivaprasad S, et al. Preferred practice pattern in central serous chorioretinopathy. Br J Ophthalmol 2017; (101): 587–90. 19 Wood EH, Karth PA, Sanislo SR, et al. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: What is the evidence? Retina 2017; (37): 1021–33. 20 Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond) 2016; 30 (10): 1371–7. 21 Alio JL, Rodriguez AE, Ferreira-Oliveira R, et al. Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study. Ophthalmol Ther 2017; (6): 285–93. 22 Garcia-Conca V, Abad-Collado M, Hueso-Abancens JR, et al. Efcacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol 2018 DOI: 10.1111 / aos. 13907 23 Kim KM, Shin YT, Kim HK. Efect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol 2012; (56): 544–50. 24 Marquez-de-Aracena R, Montero-de-Espinosa I, Munoz M, et al. Subconjunctival application of plasma platelet concentrate in the treatment of ocular burns: Preliminary results. Arch Soc Esp Oftalmol 2007; (82): 475–81. 25 Pezzotta S, Del Fante C, Scudeller L, et al. Autologous platelet lysate for treatment of refractory ocular GVHD. Bone Marrow Transplant 2012; (47): 1558–63. 26 Ghodasra DH, Fante R, Gardner TW, et al. Safety and feasibility of quantitative multiplexed cytokine analysis from ofce-based vitreous aspiration. Invest Ophthalmol Vis Sci 2016; (57): 3017–23. 27 Jung SH, Kim KA, Sohn SW, et al. Cytokine levels of the aqueous humour in central serous chorioretinopathy. Clin Exp Optom 2014; (97): 264–9. 28 Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 2011; (31): 1937–43. 29 Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010; (30): 1465–71. 30 Terao N, Koizumi H, Kojima K, et al. Association of Upregulated Angiogenic Cytokines with Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy. Invest Ophthalmol Vis Sci 2018; 59 (15): 5924–31.